Pfizer tests new drug interaction in tiny study
NCT ID NCT07335419
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial in 12 healthy adults looks at how the antifungal drug itraconazole changes the way the body processes Pfizer's experimental drug PF-07248144. Participants take PF-07248144 alone and then again with itraconazole to compare drug levels and safety. The goal is to understand dosing adjustments if these drugs are ever used together.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PF-07248144 and itraconazole
- What this could lead to
- If successful, this study will help determine safe dosing of PF-07248144 when taken with other drugs that affect liver enzymes.
- What could go wrong
- This is a very early Phase 1 trial in only 12 healthy people, not patients. It only tests drug interactions, not whether PF-07248144 works for any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer Clinical Research Unit - New Haven
New Haven, Connecticut, 06511, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill ACC017 be safely dosed? a trial seeks answers
- Can a fingerprint scan replace traditional drug tests?
- Gut feeling: could probiotics soothe the mind?
- A window to the brain? eye signals may track dopamine
- Can a common heartburn pill change how a cancer drug works?
- Breathing exercises may rewire tongue control — a pilot study puts the idea to the test